Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GNFMC
ADC Name
LMB-7
Synonyms
B3 (Fv) PE 38; LMB 7; LMB-7; LMB7; NSC 658931
   Click to Show/Hide
Organization
National Cancer Institute
Drug Status
Phase 1
Antibody Name
Murine mAb B3
  Antibody Info 
Antigen Name
Poly [ADP-ribose] polymerase 1 (PARP1)
  Antigen Info 
Payload Name
Pseudomonas exotoxin PE38
  Payload Info 
Therapeutic Target
Eukaryotic elongation factor 2 kinase (EEF2K)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
Indication Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 New Drug Application Approved
Brain cancer
1 Trials
Trial ID
NCT00003020
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT00003020
PHASE1
Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms

   Click to Show/Hide
Undisclosed  NCT00003020
Phase 1
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Key disease criteria include histologically confirmed CNS/extraneural tumors with ≥30% B3 antibody reactivity in CSF/tumor cells. Patient requirements: age ≥18, Karnofsky 50-100%, adequate hematologic/renal/hepatic function
Administration Dosage
.
Related Clinical Trial
NCT Number NCT00003020  Clinical Status PHASE1
Clinical Description Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Patients with leptomeningeal metastases.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT00003020  Clinical Status Phase 1
Clinical Description Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
References
Ref 1 LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
Ref 2 Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms